Locally Advanced or Metastatic HR+/HER2- Breast Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Locally Advanced or Metastatic HR+/HER2- Breast Cancer Emerging Therapy and TPP Insights

Thelansis’s “Locally Advanced or Metastatic HR+/HER2- Breast Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Locally Advanced or Metastatic HR+/HER2- Breast Cancer Overview

Locally advanced or metastatic HR+/HER2- breast cancer is driven by estrogen receptor signaling and represents the most common mBC subtype. Because biomarker discordance and acquired mutations are common, comprehensive molecular profiling (ESR1, PIK3CA, AKT1, PTEN, gBRCA) is mandatory. The frontline standard remains CDK4/6 inhibitors combined with endocrine therapy. Upon progression, management relies heavily on precision medicine: PIK3CA-mutated tumors are treated with inavolisib or alpelisib, capivasertib targets PIK3CA/AKT1/PTEN-altered disease, and the oral SERD elacestrant addresses ESR1-mutated, endocrine-resistant tumors. Patients with germline BRCA mutations benefit from PARP inhibitors (olaparib, talazoparib). Crucially, traditional salvage chemotherapy is being rapidly displaced by antibody-drug conjugates (ADCs); sacituzumab govitecan and trastuzumab deruxtecan—now approved even for HER2-low and HER2-ultralow expression—serve as preferred later-line standards. Management remains incurable but increasingly prolonged, requiring bone-modifying agents and early palliative integration to optimize quality of life.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)